-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Ocular Therapeutix with Outperform Rating, Announces Price Target of $17

Benzinga·03/18/2025 15:32:17
Listen to the news
RBC Capital analyst Luca Issi initiates coverage on Ocular Therapeutix (NASDAQ:OCUL) with a Outperform rating and announces Price Target of $17.